Floatz logo

Therapeutic Asset Ratings

137 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Fosifloxuridine Nafalbenamide
Metastatic Malignant Neoplasm
NuCana plcP1/2C (37)
[68Ga]Ga-ABY-025
Metastatic Malignant Neoplasm
Vanderbilt-Ingram Cancer CenterEarly P1C (36)
Evolocumab
Metastatic Cancer
CHU de Quebec-Universite LavalEarly P1C (36)
Ezetimibe
Metastatic Cancer
CHU de Quebec-Universite LavalEarly P1C (36)
il-15 enhanced engineered nk cells
Metastatic Malignant Neoplasm
Genovn Therapeutics (Suzhou) Co., Ltd.Early P1C (36)
Lipitor
Metastatic Cancer
CHU de Quebec-Universite LavalEarly P1C (36)
ALECTINIB
Metastatic Malignant Neoplasm
Seoul National University Bundang HospitalD (30)
Autologous Immune Cells
Metastatic Malignant Neoplasm
Shanghai Pudong HospitalN/AD (30)
Copper Cu 64 Anti-Cea Monoclonal Antibody M5A
Metastatic Malignant Neoplasm
City of Hope Medical CenterN/AD (30)
Datopotamab Deruxtecan
Metastatic Cancer
Hellenic Cooperative Oncology GroupD (30)
Pralsetinib, trans-
Metastatic Malignant Neoplasm
Seoul National University Bundang HospitalD (30)
Tisagenlecleucel
Metastatic Cancer
National Cancer Institute (NCI)D (30)
Showing 126 to 137 of 137 assets
PreviousPage 6 of 6Next